DEBRA VANCE: Open Payments
NPI 1366922536 · FINDLAY, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,002 in 54 payments from 13 companies in 2025. Trend: 2023 $19 · 2024 $109 · 2025 $1,002
Food & beverage: $1,002
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $185 |
| ABBVIE INC. | 12 | $183 |
| Phathom Pharmaceuticals, Inc. | 8 | $117 |
| Ardelyx, Inc. | 4 | $88 |
| Madrigal Pharmaceuticals | 1 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $64 |
| Aimmune Therapeutics, Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| GENZYME CORPORATION | 3 | $47 |
| Lilly USA, LLC | 2 | $47 |
Products named: ENTYVIO, VOQUEZNA, DUPIXENT, IBSRELA, REZDIFFRA, XIFAXAN, SKYRIZI, RINVOQ.
Industry payments across OH — which companies pay providers there.
